Michael David Fratkin, MD | |
2440 23rd St Ste B, Eureka, CA 95501-3203 | |
(707) 442-5683 | |
Not Available |
Full Name | Michael David Fratkin |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 2440 23rd St Ste B, Eureka, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1508892738 | NPI | - | NPPES |
00G833640 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | G83364 (California) | Secondary |
174400000X | Specialist | G83364 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Michael David Fratkin, MD 2440 23rd St Ste B, Eureka, CA 95501-3203 Ph: (707) 442-5683 | Michael David Fratkin, MD 2440 23rd St Ste B, Eureka, CA 95501-3203 Ph: (707) 442-5683 |
News Archive
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.
Schizophrenia, a psychiatric disorder that affects about 1% of the population,is a leading cause of functional disability in the United States.
A potent cancer-fighting molecule in our cells can be reawakened by reducing levels of a protein - called SET - that's often found in excess in cancer cells, a new study from Columbia University's Herbert Irving Comprehensive Cancer Center has found.
Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.
› Verified 4 days ago